This project will assess how depression, preclinical AD, and antidepressants affect driving behavior in cognitively normal older adults (65 years).
The long-term goal is to accurately identify who is at risk of decline in driving, to forecast when decline will occur, and to intervene before decline, thereby reducing the numbers of crashes, injuries, and death in older adults. The findings indicate that the long preclinical stage of Alzheimer disease (AD), as reflected in amyloid imaging and cerebrospinal fluid (CSF) biomarkers among cognitively normal participants, is associated with poorer driving performance on a standardized road test. This project will assess how depression, preclinical AD, and antidepressants affect driving behavior in cognitively normal older adults (65 years).
Study Type
OBSERVATIONAL
Enrollment
150
A dosage range between 6.5 - 10.0 mCi (240-370MBq) is planned for \[18F\] AV-1451. A PET-certified medical professional will prepare and administer the \[18F\] AV-1451tracer. Prior to the administration, the dosage will be assayed in a dose calibrator. The volume of 18F-AV-1451 dose should not be adjusted by adding normal saline to the syringe. Participants will receive a maximum intravenous bolus injection of 10.0 mCi of \[18F\] AV-1451 followed by a 10 mL flush of 0.9% sodium chloride (normal saline).
A dosage range between 6.0 - 20.0 mCi (222-740 MBq) is planned for \[11C\] PIB. A PET-certified medical professional will prepare and administer the \[11C\] PIB tracer. Prior to the administration, the dosage will be assayed in a dose calibrator and diluted with 0.9% sodium chloride (normal saline) up to a total 20 mL syringe volume. Participants will receive a maximum intravenous bolus injection of 20.0 mCi of \[11C\] PIB followed by a 10 mL 0.9% sodium chloride (normal saline) flush.
Washington University School of Medicine
St Louis, Missouri, United States
RECRUITINGLatitude via DRIVES chip
The latitude coordinate of the location of the vehicle being driven
Time frame: Daily for up to five years
Longitude via DRIVES chip
The Longitude coordinate of the location of the vehicle being driven
Time frame: Daily for up to five years
Vehicle Speed via DRIVES chip
The speed at which the vehicle being driven is moving.
Time frame: Daily for up to five years
Speed Limit via DRIVES chip
The posted speed limit for the location that participant is driving.
Time frame: Daily for up to five years
Difference via DRIVES chip
The difference between the speed at which the vehicle is moving and the posted speed limit for the location.
Time frame: Daily for up to five years
Event Name via DRIVES Chip
Name of the geofence in which participant had a driving event.
Time frame: Daily for up to five years
Address via DRIVES chip
Address of the location in which participant had a driving event.
Time frame: Daily for up to five years
Event Type via DRIVES chip
Enumeration describing the type of event: ignition on, heartbeat, ignition off, braking, acceleration, overspeeding, idling, low fuel, cornering, low battery event, diagnostic event triggered.
Time frame: Daily for up to five years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Event Time via DRIVES chip
Timestamp in GMT on which the event occurred.
Time frame: Daily for up to five years
Odometer Reading via DRIVES chip
Odometer reading of the vehicle.
Time frame: Daily for up to five years
Trip Distance via DRIVES chip
Total distance covered during the trip
Time frame: Daily for up to five years
Peak Speed via DRIVES chip
Highest speed attained by the vehicle during the trip.
Time frame: Daily for up to five years
Average Speed
Average trip speed of the vehicle.
Time frame: Daily for up to five years
Initial Speed via DRIVES chip
Speed at the beginning of the trip.
Time frame: Daily for up to five years
Final Speed via DRIVES chip.
Speed at the end of the trip.
Time frame: Daily for up to five years
Trail Making A
This will be tested annually in a private office setting using paper and pen assessments. This will test executive function.
Time frame: Annually for up to five years
Trail Making B
This will be tested annually in a private office setting using paper and pen assessments. This will test executive function.
Time frame: Annually for up to five years
Montreal Cognitive Assessment (MoCA) Total
This will be tested annually in a private office setting using paper and pen assessments. This will screen for cognitive impairment.
Time frame: Annually for up to five years
Category Fluency
This will be tested annually in a private office setting using paper and pen assessments. This will test language ability.
Time frame: Annually for up to five years
Phonemic Fluency
This will be tested annually in a private office setting using paper and pen assessments. This will test language ability.
Time frame: Annually for up to five years
Mini Mental Status Exam
This will be tested annually in a private office setting using paper and pen assessments. This will screen for cognitive impairment.
Time frame: Annually for up to five years
Clinical Dementia Rating (CDR) Sum of Boxes
This will be tested annually in a private office setting using paper and pen assessments. This will test for cognitive impairment/dementia severity.
Time frame: Annually for up to five years